Friedreich’s Ataxia: Drug Enters Phase 2b Clinical Trial

Edison Pharmaceuticals has launched a phase 2b trial to test its small-molecule drug EPI-743 in adults with Friedreich's ataxia

Article Highlights:
  • Edison Pharmaceuticals will test its experimental compound EPI-743 at three sites around the U.S. in 60 adults, ages 18-45 years old, who have Friedreich's ataxia.
  • EPI-743 is a small-molecule, oral drug that is designed to enter the central nervous system and synchronize energy generation in mitochondria, the energy-producing subunits in cells.
  • The drug also is being tested in metabolic diseases of muscle and mitochondrial myopathies.
by Amy Madsen on January 16, 2013 - 5:00am

Update (Dec. 30, 2013): This study of EPI-743 in Friedreich's ataxia is ongoing but is no longer open to new participants.

Edison Pharmaceuticals has launched a phase 2b clinical trial of its experimental drug EPI-743 in adults with Friedreich's ataxia (FA) to assess whether the drug has positive effects on visual function, neurological and neuromuscular function, and disease-associated biomarkers.

EPI-743 is a small-molecule, oral drug that is designed to enter the central nervous system and synchronize (improve) energy generation in mitochondria, the energy-producing subunits in cells. It is being developed by Edison, which is located in Mountain View, Calif., and Utrecht, Netherlands.

The U.S. National Institutes of Health (NIH) also is testing this molecule in a broader range of neuromuscular disorders — all metabolic diseases of muscle and mitochondrial myopathies.

Trial to be held at three sites

Investigators plan to enroll 60 adults, ages 18-45 years. Trial participants will be assigned to take either 200 or 400 milligrams of EPI-743, or a placebo, three times a day for six months. In a planned extension study, all trial participants will take EPI-743.

Prospective participants must have a genetically confirmed diagnosis of FA and meet additional trial inclusion criteria.

The trial is being conducted at three centers in the United States. (At the time this article was posted, not all study sites had started recruiting for the trial.)

Children's Hospital of Philadelphia

Philadelphia, Pa.
Contact: Lauren Sayer at seyerl@email.chop.edu

University of California, Los Angeles

Los Angeles, Calif.
Contact: Maria Casado at mcasado@mednet.ucla.edu

University of South Florida

Tampa, Fla.
Contact: Kelly Sullivan at kbarber@health.usf.edu

For more information

For details about the new trial, see:

Or, go to ClinicalTrials.gov, and enter NCT01728064 in the search box.

About Clinical Trials

About Clinical Trials

A clinical trial is a test, in humans, of an experimental treatment. Although it's possible that benefit may be derived from participating in a clinical trial, it's also possible that no benefit, or even harm, may occur.

MDA has no ability to influence who is chosen to participate in a clinical trial.

To learn more, see Learn About Clinical Studies and Being a Co-Adventurer, which is about neuromuscular disease clinical trials. To see a continuously updated database of clinical trials, go to ClinicalTrials.gov.

Your rating: None Average: 3 (1 vote)
MDA cannot respond to questions asked in the comments field. For help with questions, contact your local MDA office or clinic or email publications@mdausa.org. See comment policy